Alluvi, known as BI 4744, offers a significant breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates compelling results in patient trials, potentially surpassing current https://thefairlist.com/story12441318/alluvi-a-detailed-investigation-into-the-medication-s-prospects